GRIN2A null variants confer a high risk for early-onset schizophrenia and other mental disorders and potentially enable precision therapy

Johannes R. Lemke(Leipzig University), Steffen Syrbe(Heidelberg University), Sarah Weckhuysen(University of Antwerp), Juliette Piard(Centre Hospitalier Universitaire de Besançon), Dana Marafie(Baylor College of Medicine), Mikaël Mathot(CHU Dinant Godinne UCL Namur), Dirk Alexander Wittekind(Leipzig University), Henrike Heyne(Hasso Plattner Institute), Tim A. Benke(University of Colorado Denver), Ilona Krey(Leipzig University), Stephen F. Traynelis(Emory University), Isabella Herman(Texas Children's Hospital), Anup D. Patel(Nationwide Children's Hospital), Gaëtan Lesca(Hospices Civils de Lyon), Hesham Aldhalaan(King Faisal Specialist Hospital & Research Centre), Jill A. Rosenfeld(Baylor College of Medicine), Helenius J. Schelhaas(Radboud University Nijmegen), Alessandro Orsini(University of Pisa), Damien Lederer(Institute of Pathology and Genetics), Anne de Saint Martin(Epilepsy Foundation), Sarah Baer(Centre National de la Recherche Scientifique), Frauke Hornemann(Klinikum Chemnitz), Danique R.M. Vlaskamp(University Medical Center Groningen), Vincent Strehlow(MACOM (United States)), Bernt Popp(Berlin Institute of Health at Charité - Universitätsmedizin Berlin), Rikke S. Møller(University of Southern Denmark), Pierangelo Veggiotti(University of Pavia), Andrea Eoli(Hasso Plattner Institute), Trine Ingebrigtsen(Oslo University Hospital), Anna‐Leena Vuorinen(University of Helsinki), Chelsey Stillman(University of Colorado Anschutz Medical Campus), Trine Bjørg Hammer(Copenhagen University Hospital)
Molecular Psychiatry
October 14, 2025
Cited by 7


Related Papers